J3401 HCPCS Level II code: Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
J3401 is the HCPCS code for “Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
Short description: Vyjuvek 5x10^9pfu/ml, 0.1 ml
HCPCS · United States
Medicare details
The indicators CMS publishes with J3401 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2024
Where J3401 sits
- 1J codesDrugs administered other than orally
- 2Active code J3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3401 mean?
J3401 is the HCPCS code for “Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3401?
CMS lists J3401’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3401
All J codesJ3394Injection, lovotibeglogene autotemcel, per treatmentJ3396Injection, verteporfin, 0.1 mgJ3397Injection, vestronidase alfa-vjbk, 1 mgJ3398Injection, voretigene neparvovec-rzyl, 1 billion vector genomesJ3399Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomesJ3400Injection, triflupromazine hcl, up to 20 mgJ3402Injection, remestemcel-l-rknd, per therapeutic doseJ3403Revakinagene taroretcel-lwey, per implantJ3404Injection, zopapogene imadenovec-drba suspension, per therapeutic doseJ3405Injection, onasemnogene abeparvovec-brve, per treatmentJ3406Injection, omidubicel-onlv, per therapeutic doseJ3410Injection, hydroxyzine hcl, up to 25 mg